Navigation Links
Edison expands international biotechnology presence with launch of full coverage of Athersys
Date:11/15/2013

LONDON, Nov. 15, 2013 /PRNewswire/ -- Edison Investment Research, a leading international investment research firm, announces the launch of full coverage of Athersys, a NASDAQ-listed investment company focused on the development of MultiStem (allogeneic stem cells) for a range of indications.

Edison's comprehensive report, Multipotent stem cells, was published on 25 October and examines the investment case for the development of Athersys's allogeneic (off-the-shelf), multipotent adult progenitor cells (MAPCs), derived from adult bone marrow.

The analysis by Christian Glennie, an analyst on Edison's healthcare team, indicates that the near-term investment case for Athersys rests on the outcome of two Phase II studies of its novel, off-the-shelf, stem cell therapy product, MultiStem. Trial results in Q114 for ulcerative colitis (UC) and Q214 for ischaemic stroke have the potential to re-rate the stock and enhance the company's options for fresh finance, although a newly secured two-year, $25m equity agreement with Aspire Capital provides financial flexibility. Christian values Athersys at $205m, or $3.40 per share, ahead of the key catalysts.

For the full report see: For the full report see: www.edisoninvestmentresearch.com/research/company/athersys

The launch of coverage on Athersys is part of a programme of research initiations on biotechnology companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its healthcare research team has a range of coverage across small-, mid- and large-cap companies. All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:

Christian Glennie      Edison Investment Research      +44 (0)20 3077 5727 
healthcare@edisongroup.com

About Athersys

Athersys is a US biotechnology company focused on the development of its MultiStem cell therapy technology, with potential for cardiovascular, neurological, inflammatory and immune disease areas. Phase II studies in ulcerative colitis (Pfizer partnered) and ischaemic stroke are ongoing. Athersys is seeking partners for a 5-HT2c agonist in obesity/schizophrenia.


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Stanford scientists spark new interest in the century-old Edison battery
2. CellHealth Institute is Named 2013 Edison Award Winner
3. Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
4. UV Flu Technologies Expands Its International Footprint
5. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
6. Ansell Limited Expands Korean Presence
7. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
8. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
9. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
10. IntelliCell BioSciences Expands Management Team
11. Questcor Pharmaceuticals Expands Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... and GERMANTOWN, Maryland , February ... Prime Standard: QIA) today announced the introduction of more ... expression profiling, expanding QIAGEN,s portfolio of Sample to Insight ... to select from over 20,000 human genes and lncRNA ... genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which has created ... pursue the highest level of accuracy and quality with the addition of two ... AR5 Refractometer. Accurate, reliable and tough enough for the most demanding applications, ...
(Date:2/10/2016)... Early-career researchers from ... , Uganda and Yemen ... nutrition   Indonesia , Nepal ... Yemen are being honored for their accomplishments in ... celebrated for mentoring young women scientists who are pursuing careers in agriculture, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
Breaking Biology News(10 mins):